Forex volatility impacting reported margins
Mark-to-market forex losses of INR 41 crore in Q2 distorted EBITDA margin; continued volatility could mask underlying performance.
medium · management_commentary
Ajanta Pharma Limited — Q2 FY26
Ajanta Pharma delivered a strong Q2 FY26 with revenue of INR 1,354 crore (+14% YoY) and PAT of INR 260 crore (+20% YoY).
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
IQVIA data anomaly in cardiology segment
IQVIA reports Ajanta's cardiology growth at 6% vs IPM's 12%, but management claims internal sales match IPM; discrepancy unresolved.
medium · analyst_questionAfrica business base effect and moderated growth
Africa pharma market expected moderated growth; high base of previous year could weigh on growth despite upgraded guidance.
low · management_commentaryInventory days may inch up from current low levels
Management noted current 56-day inventory is not sustainable and expects it to rise to ~65 days, potentially impacting working capital.
low · management_commentary